Rationale for stem cell therapy for type 2 diabetes mellitus

Main Article Content

Kumar Sushaniba


Stem cells can be differentiated into many types of mature cells. Among degenerative diseases, type 1 diabetes mellitus (T1DM) is considered to be a good target disease for stem cell therapeutic application. Indeed, several studies have suggested that stem cells can be differentiated, both in vitro and in vivo, into beta cells which regenerate the pancreas. However, recent studies have shown that stem cell therapy can also provide benefits for type 2 diabetes mellitus (T2DM), which is not related to beta cell degeneration in the pancreas. This commentary will discuss the opportunity to use mesenchymal stem cells (MSCs) to treat T2DM, citing various stem cell therapies from recent published studies. Indeed, a current report “Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus, Biomedical Research and Therapy, 3(12): 1034-1044” evaluated and confirmed the positive effects of stem cell transplantation for blood glucose regulation in T2DM.


Antuna-Puente, B., Feve, B., Fellahi, S., and Bastard, J.P. (2008). Adipokines: the missing link between insulin resistance and obesity. Diabetes & metabolism 34, 2-11.
Bhansali, S., Dutta, P., Kumar, V., Yadav, M.K., Jain, A., Mudaliar, S., Bhansali, S., Sharma, R.R., Jha, V., Marwaha, N., et al. (2017). Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study. Stem cells and development.
DeFuria, J., Belkina, A.C., Jagannathan-Bogdan, M., Snyder-Cappione, J., Carr, J.D., Nersesova, Y.R., Markham, D., Strissel, K.J., Watkins, A.A., Zhu, M., et al. (2013). B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proceedings of the National Academy of Sciences of the United States of America 110, 5133-5138.
Le, P.T.-B., Duong, T.M., Vu, N.B., and Pham, P.V. (2016). Umbilical cord derived stem cell (ModulatistTM) transplantation for severe chronic obstructive pulmonary disease: a report of two cases. Biomedical Research and Therapy, 902-909%V 903.
Liu, J., Divoux, A., Sun, J., Zhang, J., Clement, K., Glickman, J.N., Sukhova, G.K., Wolters, P.J., Du, J., Gorgun, C.Z., et al. (2009). Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nature medicine 15, 940-945.
Liu, Y., Guo, L.B., and Xu, J.K. (2016). Amniotic stem cell transplantation therapy for type 2 diabetes: 3 years' follow-up report. European review for medical and pharmacological sciences 20, 3877-3885.
Musilli, C., Paccosi, S., Pala, L., Gerlini, G., Ledda, F., Mugelli, A., Rotella, C.M., and Parenti, A. (2011). Characterization of circulating and monocyte-derived dendritic cells in obese and diabetic patients. Molecular immunology 49, 234-238.
Pham, P.V., Vu, N.B., and Phan, N.K. (2016). Umbilical cord-derived stem cells (MODULATISTTM) show strong immunomodulation capacity compared to adipose tissue-derived or bone marrow-derived mesenchymal stem cells. Biomedical Research and Therapy, 687-696%V 683.
Sangiorgi, B., and Panepucci, R.A. (2016). Modulation of Immunoregulatory Properties of Mesenchymal Stromal Cells by Toll-Like Receptors: Potential Applications on GVHD. Stem cells international 2016, 9434250.
Sell, H., Habich, C., and Eckel, J. (2012). Adaptive immunity in obesity and insulin resistance. Nature reviews Endocrinology 8, 709-716.
Talukdar, S., Oh, D.Y., Bandyopadhyay, G., Li, D., Xu, J., McNelis, J., Lu, M., Li, P., Yan, Q., Zhu, Y., et al. (2012). Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nature medicine 18, 1407-1412.
Wehbe, T., Chahine, N.A., Sissi, S., Abou-Joaude, I., and Chalhoub, L. (2016). Bone marrow derived stem cell therapy for type 2 diabetes mellitus. Stem cell investigation 3, 87.
Wu, D., Molofsky, A.B., Liang, H.E., Ricardo-Gonzalez, R.R., Jouihan, H.A., Bando, J.K., Chawla, A., and Locksley, R.M. (2011). Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (New York, NY) 332, 243-247.
Xv, J., Ming, Q., Wang, X., Zhang, W., Li, Z., Wang, S., Li, Y., and Li, L. (2016). Mesenchymal stem cells moderate immune response of type 1 diabetes. Cell and tissue research.


Download data is not yet available.

Article Details

How to Cite
SUSHANIBA, Kumar. Rationale for stem cell therapy for type 2 diabetes mellitus. Biomedical Research and Therapy, [S.l.], v. 4, n. 02, p. 1166-1170, feb. 2017. ISSN 2198-4093. Available at: <http://www.bmrat.org/index.php/BMRAT/article/view/152>. Date accessed: 23 oct. 2017. doi: https://doi.org/10.15419/bmrat.v4i02.152.
Short Communication